Downregulation of miR-124 drives metabolic and proliferative abnormalities in PAH endothelial cells, identifying it as a potential novel therapeutic target.
Pulmonary vascular and circulating progenitor endothelial cells isolated from patients with PAH demonstrate downregulation of miR-124, leading to the metabolic and proliferative abnormalities in PAH ECs via PTPB1 and PKM1/PKM2. Therefore, the manipulation of this miRNA or its targets could represent a novel therapeutic approach for the treatment of PAH.
Caruso et al. (Tue,) studied this question.